Global Point of Care
Mobile Navigation button

ID NOW™ COVID-19

Molecular. In minutes. On the front line.

ID NOW™ is a leading molecular point-of-care platform in the United States, trusted by hospitals, physician offices, and urgent care clinics nationwide.

The ID NOW™ COVID-19 assay is now available for use on the ID NOW platform under U.S. Food and Drug Administration Emergency Use Authorization (EUA). The ID NOW™ COVID-19 rapid test delivers high-quality molecular positive results in as little as 5 minutes, targeting the coronavirus (COVID-19) RdRp Gene.

Timely results enable healthcare professionals to make appropriate and more efficient treatment and infection control decisions. EUA supports flexible near patient testing environments.

Only available in the US.

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an
emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only
for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the
duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic
tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
authorization is terminated or revoked sooner.

1. Please see ID NOW Instrument User manual for additional operating environment requirements.

   

False
accessibility

   

YesNo
accessibility

   

YesNo
More Info